Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19477950 | 0.81 | TRPV1 (0.41) | CA14CA12CA1CA2MMP1 | |
| SCHEMBL15562023 | 0.79 | TP53 (0.32) | TP53CA14CYP2D6CYP2C19 | |
| SCHEMBL4440551 | 0.78 | POLB (0.40) | CYP2D6CYP2C19CA12CA1CA2 | |
| SCHEMBL28719441 | 0.76 | CYP2D6 (0.41) | TP53CYP2D6CYP2C19CA12CA1 | |
| SCHEMBL2026408 | 0.76 | MGAM (0.34) | CYP2D6CYP2C19MMP8SMN1; SMN2 | |
| SCHEMBL2024610 | 0.74 | SLC1A3 (0.41) | CYP2D6CYP2C19 | |
| SCHEMBL25170149 | 0.74 | MLYCD (0.30) | — | |
| SCHEMBL23457853 | 0.74 | — | — | |
| SCHEMBL16823439 | 0.74 | TP53 (0.40) | TP53CYP2D6CYP2C19 | |
| SCHEMBL14952782 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3374359-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017080979-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-05-18 | — | — | WO | disclosed |
| WO-2016162325-A1 | SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-A]PYRAZIN-1 (2H)-ONE DERIVATIVES AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2016-10-13 | — | — | WO | disclosed |
| WO-2014178082-A1 | NOVEL 2'/3'/5'-(R/S)-SERINYL FUNCTIONALIZED OLIGONUCLEOTIDES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014022752-A1 | MACROCYCLES AS PIM INHIBITORS | AMGEN INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-2516434-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |